Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

计划入组 43 人 · 首次发布于 2024 年 4 月 30 日

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

计划入组 38 人 · 首次发布于 2017 年 10 月 16 日

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

计划入组 34 人 · 首次发布于 2015 年 8 月 21 日

Trilaciclib(Cosela)

C₂₄H₃₀N₈O · Rx

CDK6 inhibitors (cancer)

CDK4/6i(Novartis)

Biotheryx Completes Enrollment in Phase 1a Trial of First-in-Class CDK4/6 Degrader BTX-9341 for HR+/HER2- Breast Cancer

Biotheryx Advances BTX-9341 CDK4/6 Degrader into Dose Expansion Phase for HR+/HER2- Breast Cancer

Monte Rosa Presents Promising Preclinical Data for CDK2 Molecular Glue Degrader in HR-Positive Breast Cancer at AACR 2025